Presentations July 2022 Investor Presentation ASGCT 2022 presentation ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene TIDES 2022: In Vivo CRISPR Base Editing to Treat ASCVD Keystone Symposia 2022: Off-target Analyses ACC 2022: Sequential in vivo CRISPR base editing of the PCSK9 and ANGPTL3 genes in NHPs Verve Therapeutics Presentation at the 40th Annual J.P. Morgan Healthcare Conference In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia Targeted Delivery of Base Editors to Hepatocytes In Vivo Safety and Durability of VERVE-101
July 2022 Investor Presentation ASGCT 2022 presentation ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene TIDES 2022: In Vivo CRISPR Base Editing to Treat ASCVD Keystone Symposia 2022: Off-target Analyses ACC 2022: Sequential in vivo CRISPR base editing of the PCSK9 and ANGPTL3 genes in NHPs Verve Therapeutics Presentation at the 40th Annual J.P. Morgan Healthcare Conference In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia Targeted Delivery of Base Editors to Hepatocytes In Vivo Safety and Durability of VERVE-101
ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene
In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia